Safety and Effectiveness of LY-CoV555 in Patientsadmin4821
Annandale, VA; October 5, 2020
CARE-ID announced it is continuing the clinical research study to evaluate the safety and effectiveness of LY-CoV555 in patients with early mild to moderate COVID-19. Sponsored by Eli Lilly and Company (Lilly), the BLAZE-1 Study is looking for adults ages 18 or older who have recently tested positive for COVID-19 and are not hospitalized. Several weeks ago, CARE-ID reached is target enrollment and re-directed it resources to the Pfizer vaccine study. Due to the nature of the 2 studies (one treatment and the other vaccine) it was critically important to maintain strict separation of the two study populations. Pfizer, however, within the past week has moved to re-allocate volunteer slots to geographies with higher infection rates in the general population. This pause in the vaccine study for CARE-ID makes it possible to reenergize its focus on the antibodies study.